Alnylam Gene-Silencing Therapy to Treat Kidney Disorder Succeeds in Late-Stage Study Alnylam Gene-Silencing Therapy to Treat Kidney Disorder Succeeds in Late-Stage Study

Alnylam Pharmaceuticals Inc ' s gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Nephrology News Source Type: news